Adagene Inc.
NASDAQ:ADAGBiotechnology
+$0.13 today
- Market cap
- $68.52M
- Beta
- 0.59
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$0.47
Volume 1.30M
Average 0.21M
ADAG Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Adagene Inc.NASDAQ: ADAG
Research & Development · Q4 FY2025 · quarter ended Dec 2025
Research & development declines year over year
Q4 FY2025 research & development of $9.76M fell 52.4% year over year, behind the -47.7% change in trailing-twelve-month research & development. Over 3 fiscal years it compounded at -35.3% a year.
Context
- Research & development amounted to 287.2% of revenue in FY2025, down 27600.6 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -52.4% toward the trailing-twelve-month pace of -47.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 22.03M USD
- Year-over-year change
- -23.4%
- 4-year CAGR
- -24.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.03M | -23.4% |
| FY2024 | 2024-12-31 | 28.78M | -21.4% |
| FY2023 | 2023-12-31 | 36.64M | -55.0% |
| FY2022 | 2022-12-31 | 81.34M | +19.4% |
| FY2021 | 2021-12-31 | 68.1M | — |
Research & Development vs competitors
How ADAG compares with its peers on the latest reported figures
- ADAG's LTM Jun 2024 research & development of $30.07M is the 5th highest of the 9 companies compared; the peer median is $25.85M.
- Research & development amounts to 3686.7% of revenue for ADAG, versus a peer median of 133.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $16.37B | +432309.4% | +1606.6% | — |
| LTM Mar 2026 | $106.27M | -5.4% | +24.0% | 1163.2% | |
| LTM Mar 2026 | $93.8M | -4.5% | +11.6% | — | |
| LTM Mar 2026 | $40.98M | +3.6% | +14.5% | — | |
| LTM Jun 2024 | $30.07M | — | -35.3% | 3686.7% | |
| LTM Mar 2026 | $10.72M | +1.7% | +6.8% | — | |
| LTM Mar 2026 | $8.51M | -76.4% | -55.5% | 12.9% | |
| LTM Mar 2026 | $4.28M | -18.5% | -39.5% | 186.8% | |
| LTM Apr 2026 | $1.45M | -48.6% | +24.4% | 80.7% | |
| Peer median (excluding ADAG) | $25.85M | -4.9% | +13.1% | 133.7% | |
Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.18M | 9.29M | 18.11M | 103.2K | 7.67M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 10.18M | 9.29M | 18.11M | (823.04K) | 7.67M |
| Gross Margin | 100.0% | 100.0% | 100.0% | -797.5% | 100.0% |
| Research & Development | 68.1M | 81.34M | 36.64M | 28.78M | 22.03M |
| Selling, General & Admin | 14.44M | 11.87M | 8.67M | 7.27M | 7.08M |
| Operating Expenses | 82.54M | 93.21M | 41.83M | 36.05M | 29.11M |
| Depreciation & Amortization | 1.13M | 1.43M | 1.21M | 926.25K | 589.79K |
| EBITDA | (69.99M) | (77.39M) | (14.95M) | (31.66M) | (16.85M) |
| EBITDA Margin | -687.8% | -832.8% | -82.5% | -30680.5% | -219.7% |
| Operating Income | (72.36M) | (83.92M) | (23.72M) | (35.95M) | (21.44M) |
| Operating Margin | -711.2% | -903.1% | -131.0% | -34835.4% | -279.5% |
| Interest Income | 76.17K | 377.5K | 4.28M | 3.8M | 2.3M |
| Interest Expense | 363.76K | 693.32K | 1.11M | 851.87K | 463.13K |
| Other Income / Expenses | 887.77K | 4.41M | 6.46M | 2.51M | 3.53M |
| Income Before Tax | (71.48M) | (79.51M) | (17.25M) | (33.44M) | (17.91M) |
| Pre-Tax Margin | -702.5% | -855.6% | -95.3% | -32403.5% | -233.4% |
| Income Tax Expense | 1.7M | 459.06K | 1.69M | (17.55K) | (297.86K) |
| Net Income | (73.18M) | (79.97M) | (18.95M) | (33.42M) | (17.61M) |
| Net Margin | -719.2% | -860.6% | -104.6% | -32386.4% | -229.6% |
| EPS (Basic) | (2.29) | (2.31) | (0.55) | (0.95) | (0.46) |
| EPS (Diluted) | (2.29) | (2.31) | (0.54) | (0.95) | (0.46) |
| Weighted Avg Shares | 32.02M | 34.65M | 34.64M | 36.02M | 37.76M |
| Weighted Avg Shares (Diluted) | 32.02M | 34.65M | 35.03M | 36.02M | 37.76M |
Adagene Inc.
NASDAQ:ADAG
Intrinsic Alpha fair value
Locked
Current Price
$1.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.